Five things for pharma marketers to know: Monday, October 3, 2016
More drugmakers file lawsuits to prevent biosimilar competition; experimental dermatitis drug showeds promising results; pharma blames PBMs for price hikes
Biosimilars
The FDA approves Amgen’s biosimilar version of Humira
Amgen’s drug is set to compete with AbbVie’s Humira, which is the second-best selling drug in the U.S. in 2015.
Five things for pharma marketers to know: Wednesday, August 31, 2016
The FDA approves an Enbrel biosimilar; Express Scripts to launch program to reduce diabetes costs; a GSK vaccine beats sales forecasts
Five things for pharma marketers to know: Thursday, August 18, 2016
Court clears Pfizer to move ahead with Remicade biosimilar; McDonald’s yanks activity trackers over skin irritation; California drug-pricing bill pulled
Five things for pharma marketers to know: Friday, July 22, 2016
Herceptin biosimilar meets endpoint in clinical trial; Roche plans to launch five new drugs over the next year; government seeks to block insurer deals
Five things for pharma marketers to know: Thursday, July 14, 2016
The FDA expands use for Pfizer’s Prevnar 13 vaccine; an FDA panel votes in support of Novartis biosimilar; U.S. healthcare spending rises 5.5% in 2015
What do physicians think about biosimilars?
A Sermo poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?”
Merck educates doctors about biosimilars, long before it will sell one in the U.S.
Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.
Five things for pharma marketers to know: Friday, May 6, 2016
Investigation says Oxycontin wears off sooner than it claims; PBMs and insurers anticipate high biosimilar prices; Valeant forms pricing committee
Infographic: the growing biosimilar market in the U.S.
The FDA has approved two biosimilars, but questions remain about how quickly providers and patients in the U.S. will adopt them.
